HR 7837
Most Favored Patient Act of 2026
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:12 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Most Favored Patient Act of 2026, directs the Center for Medicare and Medicaid Innovation to test a model that would require drug manufacturers to provide their most-favored-nation (MFN) drug prices to eligible individuals and providers. The model would compare U.S. drug prices to those in other countries and establish a benchmark for pricing. It includes a 5-year testing period and establishes definitions related to the MFN pricing model and eligible participants.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.